Reported about 1 month ago
Arcutis Biotherapeutics (NASDAQ:ARQT) has enrolled its first child in the Phase 2 clinical trial, INTEGUMENT-INFANT, testing the safety of ZORYVE cream 0.05% for infants aged 3 months to under 24 months with mild to moderate atopic dermatitis. With a lack of approved treatments for this condition in infants, the trial builds upon positive findings from prior studies, aiming to address the chronic skin disorder that significantly impacts children's health and family dynamics.
Source: YAHOO